Cargando…

Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17

Spinocerebellar ataxia type 17 (SCA 17) is a polyglutamine disease caused by the expansion of CAG/CAA repeats in the TATA box-binding protein (TBP) gene. The Ginkgo biloba extract, EGb 761, contains flavonoids and terpenoids with a potential use for the treatment of neurodegenerative diseases such a...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ding-Siang, Lin, Hsuan-Yuan, Lee-Chen, Guey-Jen, Hsieh-Li, Hsiu-Mei, Wu, Chung-Hsin, Lin, Jung-Yaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762588/
https://www.ncbi.nlm.nih.gov/pubmed/26937174
http://dx.doi.org/10.2147/DDDT.S98156
_version_ 1782417134089928704
author Huang, Ding-Siang
Lin, Hsuan-Yuan
Lee-Chen, Guey-Jen
Hsieh-Li, Hsiu-Mei
Wu, Chung-Hsin
Lin, Jung-Yaw
author_facet Huang, Ding-Siang
Lin, Hsuan-Yuan
Lee-Chen, Guey-Jen
Hsieh-Li, Hsiu-Mei
Wu, Chung-Hsin
Lin, Jung-Yaw
author_sort Huang, Ding-Siang
collection PubMed
description Spinocerebellar ataxia type 17 (SCA 17) is a polyglutamine disease caused by the expansion of CAG/CAA repeats in the TATA box-binding protein (TBP) gene. The Ginkgo biloba extract, EGb 761, contains flavonoids and terpenoids with a potential use for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. The neuroprotective effects of EGb 761 are obvious, but whether the EGb 761 has therapeutic effects in SCA 17 is still unclear. To manage our issues, we have generated TBP/79Q-expressing SH-SY5Y cells and SCA 17 transgenic mice with the mutant hTBP gene. In in vitro experiment, we observed that the EGb 761 treatment decreased the amount of sodium dodecyl sulfate-insoluble proteins in the TBP/79Q-expressing SH-SY5Y cells. We further found that the EGb 761 treatment could inhibit excitotoxicity and calcium influx and reduce the expression of apoptotic markers in glutamate-treated SH-SY5Y neuroblastoma cells. In in vivo experiment, we observed that the EGb 761 treatment (100 mg/kg intraperitoneal injection per day) could relieve the motor deficiencies of the SCA 17 transgenic mice. Our findings provide evidence that the EGb 761 treatment can be a remedy for SCA 17 via suppressing excitotoxicity and apoptosis in SCA 17 cell and animal models. Therefore, we suggest that EGb 761 may be a potential therapeutic agent for treating SCA 17.
format Online
Article
Text
id pubmed-4762588
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47625882016-03-02 Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17 Huang, Ding-Siang Lin, Hsuan-Yuan Lee-Chen, Guey-Jen Hsieh-Li, Hsiu-Mei Wu, Chung-Hsin Lin, Jung-Yaw Drug Des Devel Ther Original Research Spinocerebellar ataxia type 17 (SCA 17) is a polyglutamine disease caused by the expansion of CAG/CAA repeats in the TATA box-binding protein (TBP) gene. The Ginkgo biloba extract, EGb 761, contains flavonoids and terpenoids with a potential use for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. The neuroprotective effects of EGb 761 are obvious, but whether the EGb 761 has therapeutic effects in SCA 17 is still unclear. To manage our issues, we have generated TBP/79Q-expressing SH-SY5Y cells and SCA 17 transgenic mice with the mutant hTBP gene. In in vitro experiment, we observed that the EGb 761 treatment decreased the amount of sodium dodecyl sulfate-insoluble proteins in the TBP/79Q-expressing SH-SY5Y cells. We further found that the EGb 761 treatment could inhibit excitotoxicity and calcium influx and reduce the expression of apoptotic markers in glutamate-treated SH-SY5Y neuroblastoma cells. In in vivo experiment, we observed that the EGb 761 treatment (100 mg/kg intraperitoneal injection per day) could relieve the motor deficiencies of the SCA 17 transgenic mice. Our findings provide evidence that the EGb 761 treatment can be a remedy for SCA 17 via suppressing excitotoxicity and apoptosis in SCA 17 cell and animal models. Therefore, we suggest that EGb 761 may be a potential therapeutic agent for treating SCA 17. Dove Medical Press 2016-02-18 /pmc/articles/PMC4762588/ /pubmed/26937174 http://dx.doi.org/10.2147/DDDT.S98156 Text en © 2016 Huang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Huang, Ding-Siang
Lin, Hsuan-Yuan
Lee-Chen, Guey-Jen
Hsieh-Li, Hsiu-Mei
Wu, Chung-Hsin
Lin, Jung-Yaw
Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17
title Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17
title_full Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17
title_fullStr Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17
title_full_unstemmed Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17
title_short Treatment with a Ginkgo biloba extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17
title_sort treatment with a ginkgo biloba extract, egb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762588/
https://www.ncbi.nlm.nih.gov/pubmed/26937174
http://dx.doi.org/10.2147/DDDT.S98156
work_keys_str_mv AT huangdingsiang treatmentwithaginkgobilobaextractegb761inhibitsexcitotoxicityinananimalmodelofspinocerebellarataxiatype17
AT linhsuanyuan treatmentwithaginkgobilobaextractegb761inhibitsexcitotoxicityinananimalmodelofspinocerebellarataxiatype17
AT leechengueyjen treatmentwithaginkgobilobaextractegb761inhibitsexcitotoxicityinananimalmodelofspinocerebellarataxiatype17
AT hsiehlihsiumei treatmentwithaginkgobilobaextractegb761inhibitsexcitotoxicityinananimalmodelofspinocerebellarataxiatype17
AT wuchunghsin treatmentwithaginkgobilobaextractegb761inhibitsexcitotoxicityinananimalmodelofspinocerebellarataxiatype17
AT linjungyaw treatmentwithaginkgobilobaextractegb761inhibitsexcitotoxicityinananimalmodelofspinocerebellarataxiatype17